Literature DB >> 25492616

Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, S. Zohar.

Nolan A Wages1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25492616      PMCID: PMC4264835          DOI: 10.1002/sim.6336

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


× No keyword cloud information.
  5 in total

1.  Dose-finding design for multi-drug combinations.

Authors:  Nolan A Wages; Mark R Conaway; John O'Quigley
Journal:  Clin Trials       Date:  2011-06-07       Impact factor: 2.486

2.  Continual reassessment method for partial ordering.

Authors:  Nolan A Wages; Mark R Conaway; John O'Quigley
Journal:  Biometrics       Date:  2011-03-01       Impact factor: 2.571

3.  Competing designs for drug combination in phase I dose-finding clinical trials.

Authors:  M-K Riviere; F Dubois; S Zohar
Journal:  Stat Med       Date:  2014-01-27       Impact factor: 2.373

4.  pocrm: an R-package for phase I trials of combinations of agents.

Authors:  Nolan A Wages; Nikole Varhegyi
Journal:  Comput Methods Programs Biomed       Date:  2013-07-18       Impact factor: 5.428

5.  Specifications of a continual reassessment method design for phase I trials of combined drugs.

Authors:  Nolan A Wages; Mark R Conaway
Journal:  Pharm Stat       Date:  2013-06-03       Impact factor: 1.894

  5 in total
  4 in total

Review 1.  Practical designs for Phase I combination studies in oncology.

Authors:  Nolan A Wages; Anastasia Ivanova; Olga Marchenko
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

2.  A surface-free design for phase I dual-agent combination trials.

Authors:  Pavel Mozgunov; Mauro Gasparini; Thomas Jaki
Journal:  Stat Methods Med Res       Date:  2020-04-27       Impact factor: 3.021

3.  A benchmark for dose-finding studies with unknown ordering.

Authors:  Pavel Mozgunov; Xavier Paoletti; Thomas Jaki
Journal:  Biostatistics       Date:  2022-07-18       Impact factor: 5.279

4.  Improving safety of the continual reassessment method via a modified allocation rule.

Authors:  Pavel Mozgunov; Thomas Jaki
Journal:  Stat Med       Date:  2019-12-20       Impact factor: 2.373

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.